Trade PTGX anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Protagonist Therapeutics, Inc. (PTGX) is trading at US$145.72, down 2.07% today as of Sep 4, 16:00 EDT. The company has a market capitalisation of US$9.99B. Over the past 52 weeks, PTGX has traded between US$54.50 and US$160.81. On Syfe you can trade PTGX with $0 commission and add it to your watchlist.
| Previous close | US$148.80 |
|---|---|
| Market cap | US$9.99B |
| P/E ratio | 123.73 |
| 52-week range | US$54.50 – US$160.81 |
| Volume | 500.97K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
Year: 2016
Protagonist Therapeutics, Inc. (PTGX) stock is trading at US$145.72, -2.07% from the previous close of US$148.80.
The market cap for Protagonist Therapeutics, Inc. (PTGX) stock is approximately US$9.99B.
The price-to-earnings ratio for Protagonist Therapeutics, Inc. (PTGX) is 123.73, based on the latest reported earnings.
The 52-week high for Protagonist Therapeutics, Inc. (PTGX) stock is US$160.81.
The 52-week low for Protagonist Therapeutics, Inc. (PTGX) stock is US$54.50.
Protagonist Therapeutics, Inc. (PTGX) does not currently pay a dividend.
Stay on top of PTGX
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
